Compare Stocks: ACRV, ALXO, ANIK, and SRZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.73 -0.9%	$1.66	$1.21 ▼ $3.56	$73.83M	1.85	1.02 million shs	84,466 shs
ALXO ALX Oncology	$1.97 -4.6%	$1.89	$0.60 ▼ $2.66	$264.41M	0.42	1.04 million shs	208,072 shs
ANIK Anika Therapeutics	$21.11 +2.1%	$15.82	$8.15 ▼ $22.88	$282.39M	0.2	116,057 shs	39,279 shs
SRZN Surrozen	$25.19 +0.4%	$22.87	$9.66 ▼ $35.00	$292.40M	0.52	139,353 shs	43,584 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+0.58%	+11.54%	-11.22%	-7.94%	+40.32%
ALXO ALX Oncology	-1.90%	+6.74%	-3.29%	+1.48%	+204.37%
ANIK Anika Therapeutics	-3.45%	-0.29%	+32.56%	+40.87%	+154.99%
SRZN Surrozen	-2.07%	+15.20%	+8.19%	-18.17%	+162.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.73 -0.9%	$1.66	$1.21 ▼ $3.56	$73.83M	1.85	1.02 million shs	84,466 shs
ALXO ALX Oncology	$1.97 -4.6%	$1.89	$0.60 ▼ $2.66	$264.41M	0.42	1.04 million shs	208,072 shs
ANIK Anika Therapeutics	$21.11 +2.1%	$15.82	$8.15 ▼ $22.88	$282.39M	0.2	116,057 shs	39,279 shs
SRZN Surrozen	$25.19 +0.4%	$22.87	$9.66 ▼ $35.00	$292.40M	0.52	139,353 shs	43,584 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+0.58%	+11.54%	-11.22%	-7.94%	+40.32%
ALXO ALX Oncology	-1.90%	+6.74%	-3.29%	+1.48%	+204.37%
ANIK Anika Therapeutics	-3.45%	-0.29%	+32.56%	+40.87%	+154.99%
SRZN Surrozen	-2.07%	+15.20%	+8.19%	-18.17%	+162.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.60	Moderate Buy	$11.67	576.33% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	134.10% Upside
ANIK Anika Therapeutics	2.75	Moderate Buy	$21.00	-0.50% Downside
SRZN Surrozen	2.67	Moderate Buy	$42.00	66.77% Upside

Current Analyst Ratings Breakdown

Latest ACRV, ALXO, ANIK, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/30/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $21.00
7/30/2026	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/26/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ANIK Anika Therapeutics	$112.82M	2.50	N/A	N/A	$9.95 per share	2.12
SRZN Surrozen	$3.48M	84.02	N/A	N/A	($19.21) per share	-1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$2.00	N/A	N/A	N/A	N/A	-64.43%	-57.08%	8/12/2026 (Estimated)
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	N/A
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	72.78	15.30	-3.14%	0.20%	0.15%	N/A
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-96.11%	N/A

Latest ACRV, ALXO, ANIK, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.49	N/A	N/A	N/A	$0.39 million	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million
5/13/2026	Q1 2026	ACRV Acrivon Therapeutics	-$0.49	-$0.49	N/A	-$0.49	$0.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	8.98	8.98
ALXO ALX Oncology	0.07	9.71	9.71
ANIK Anika Therapeutics	N/A	4.48	3.19
SRZN Surrozen	N/A	11.91	11.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ALXO ALX Oncology	97.97%
ANIK Anika Therapeutics	91.53%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
ALXO ALX Oncology	12.40%
ANIK Anika Therapeutics	12.08%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	42.80 million	38.31 million	Not Optionable
ALXO ALX Oncology	40	134.56 million	117.88 million	Optionable
ANIK Anika Therapeutics	300	13.38 million	11.77 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable

ACRV, ALXO, ANIK, and SRZN Headlines

Recent News About These Companies

HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)

August 10 at 8:17 AM | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

August 6, 2026 | marketbeat.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN

August 2, 2026 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

July 30, 2026 | marketbeat.com

Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

Surrozen Inc

July 28, 2026 | edition.cnn.com

Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock

July 28, 2026 | marketbeat.com

Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright

July 22, 2026 | msn.com

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

July 22, 2026 | marketbeat.com

Surrozen to Present at Upcoming Healthcare Investor Conference

July 15, 2026 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

July 15, 2026 | marketbeat.com

Surrozen (SRZN) Stock Forecast & Price Target

June 4, 2026 | investing.com

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Surrozen (SRZN) price target increased by 10.11% to 43.52

May 14, 2026 | msn.com

Surrozen Shareholders Support Board, Auditor and Pay Policies

May 14, 2026 | tipranks.com

Surrozen to Present at Upcoming Healthcare Investor Conference

May 12, 2026 | globenewswire.com

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026 | globenewswire.com

Insider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of Stock

May 6, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, ALXO, ANIK, and SRZN Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.72 -0.02 (-0.86%)

As of 12:15 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

ALX Oncology NASDAQ:ALXO

$1.96 -0.10 (-4.61%)

As of 12:15 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Anika Therapeutics NASDAQ:ANIK

$21.10 +0.43 (+2.06%)

As of 12:14 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Surrozen NASDAQ:SRZN

$25.18 +0.10 (+0.38%)

As of 12:12 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, ALXO, ANIK, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, ALXO, ANIK, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, ALXO, ANIK, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, ALXO, ANIK, and SRZN Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

ALX Oncology NASDAQ:ALXO

Anika Therapeutics NASDAQ:ANIK

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, ALXO, ANIK, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, ALXO, ANIK, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, ALXO, ANIK, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, ALXO, ANIK, and SRZN Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

ALX Oncology NASDAQ:ALXO

Anika Therapeutics NASDAQ:ANIK

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools